ericsphotography / iStockphoto.com
A US court handed victory to Eli Lilly late last week after finding that a drug for which Dr Reddy’s is seeking approval would infringe a patent covering cancer treatment Alimta (pemetrexed for injection).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Eli Lilly, Dr Reddy's, patent, FDA, New Drug Application, generic, patent infringement, Alimta, Food and Drug Administration